Mimedx Group Inc (MDXG) 5.71 $MDXG
Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx
PR Newswire - Thu Apr 10, 11:30AM CDT
On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 673.27, up 2.11%, and the same has advanced 2.86% in the last three months. Investor-Edge has initiated coverage on the following equities: Seattle Genetics Inc. (NASDAQ: SGEN), Theravance Inc. (NASDAQ: THRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX) and MiMedx Group Inc. (NASDAQ: MDXG). Free technical research on SGEN, THRX, NBIX and MDXG can be downloaded upon signing up at:
MiMedx First Quarter Revenue Exceeded Upper End Of Guidance
PR Newswire - Mon Apr 07, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its first quarter of 2014 revenue slightly exceeded the upper end of its previously announced guidance. The Company also announced its guidance for the second quarter of 2014.
MiMedx Group, Inc. Announces Release Date for 2014 First Quarter Results
PR Newswire - Wed Apr 02, 1:23PM CDT
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the first quarter ended March 31, 2014, will be released before the opening of the market on Friday, April 25, 2014. MiMedx will host a live broadcast of its first quarter conference call on Friday, April 25, 2014 at 10:30am EDT. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website at www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MiMedx to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Fri Mar 28, 1:22PM CDT
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 13th Annual Needham Healthcare Conference in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, April 8th at 3:00 p.m. EDT, at the Westin NY Grand Central Hotel. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx Schedules Shareholder Call To Update Progress Of FDA Discussions, Reimbursement Successes And Recent Short-Selling Initiatives
PR Newswire - Mon Mar 24, 7:34AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it will host a shareholder call tomorrow, Tuesday, March 25, 2014 at 11:00 AM Eastern Time to update shareholders on the positive progress of its discussions with the Food and Drug Administration ("FDA"
regarding the Company's micronized allograft. During the call, the Company also plans to provide updates on its progress with wound care reimbursement, its sales force expansion, as well as its reaction to the misinformation in certain recent short-selling related blogs.
MiMedx to Present at 2nd Annual Regen Med Investor Day
PR Newswire - Mon Mar 17, 10:31AM CDT
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 2nd Annual Regen Med Investor Day in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Wednesday, March 26th, 3:45 p.m. EDT, at the Metropolitan Club. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx EpiFix® Allograft Receives Medicare Coverage From The Final Medicare Contractor
PR Newswire - Thu Mar 13, 1:11PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, First Coast Service Options, Inc. ("FCSO" , has confirmed that the Company's wound care allograft, EpiFix®, has been approved for coverage when applied in the hospital outpatient and ambulatory surgery center settings.
MiMedx To Present At 2014 Canaccord Genuity Musculoskeletal Conference
PR Newswire - Tue Mar 04, 3:52PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 2014 Canaccord|Genuity Musculoskeletal Conference in New Orleans, Louisiana. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, March 11th at 10:00am CDT/11:00am EDT, at the Sheraton New Orleans. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx Announces Record 2013 Results
PR Newswire - Wed Feb 26, 6:30AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the year ended December 31, 2013.
MiMedx Sponsored Osteoarthritis Study Using PURION® Processed Amniotic Tissue Published In Arthritis Research & Therapy
PR Newswire - Tue Feb 25, 7:10PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today a MiMedx-sponsored study from Georgia Institute of Technology has been published in Arthritis Research & Therapy. The article, titled "Intra-articular injection of micronized dehydrated human amnion/chorion membrane attenuates osteoarthritis development" was authored by Nick Willett, Tanushree Thote, Angela Lin, Shamus Moran, Yazdan Raji, Sanjay Sridaran, Hazel Stevens and Robert Guldberg. The electronic publication of the study is available at http://arthritis-research.com/content/16/1/R47.
Second MiMedx EpiFix® Randomized Comparative Study Published In International Wound Journal Shows 92.5% Healing Rate Over 12 Weeks
PR Newswire - Tue Feb 25, 6:07PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "A prospective, randomized comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers" has been published electronically in the International Wound Journal. The study manuscript was authored by Charles M. Zelen, DPM, FACFAS; Thomas E. Serena MD, FACS; and Robert J. Snyder, DPM, MSc.
MiMedx EpiFix® Allograft Awarded Coverage by HCSC
PR Newswire - Wed Feb 12, 7:30AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Health Care Services Corporation (HCSC) has confirmed that the Company's EpiFix® allograft has been awarded reimbursement coverage. HCSC is the largest customer-owned health insurance company in the United States with nearly 14 million members.
RXi Pharmaceuticals Announces Listing on NASDAQ Capital Market
PR Newswire - Tue Feb 11, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced today that the Company received approval by The NASDAQ Stock Market LLC's ("NASDAQ" Listing Qualification Department to list its common stock on the NASDAQ Capital Market. The Company's common stock will commence trading under the same ticker symbol, "RXII," on the NASDAQ Capital Market effective at the opening of trading on Tuesday, February 11, 2014.
MiMedx EpiFix® Allograft Receives Reimbursement Coverage From The 7th Of The 8 Medicare Contractors
PR Newswire - Mon Feb 10, 8:03AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, Noridian Healthcare Solutions, LLC, has confirmed that the Company's wound care allograft, EpiFix®, has been approved to receive reimbursement coverage.
MiMedx Addresses Misrepresentations In Seeking Alpha Article
PR Newswire - Fri Feb 07, 2:43PM CST
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, today issued the following statement regarding a blog post published today on Seeking Alpha.
MiMedx Announces Release Date For 2013 Full Year Results
PR Newswire - Tue Jan 21, 10:08AM CST
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the fourth quarter and year ended December 31, 2013, will be released before the opening of the market on Wednesday, February 26, 2014. MiMedx will host a live broadcast of its fourth quarter and year-end conference call on Wednesday, February 26, 2014 at 10:30am EST. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website at www.mimedx.com or at www.earnings.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com or www.earnings.com.
MiMedx to Present at 32nd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Jan 13, 10:23AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced the schedule for its presentation at the 32nd Annual J.P. Morgan Healthcare Conference. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, will present on Thursday, January 16, 2014, 9:00am PST, at the Westin St. Francis Hotel in San Francisco. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
NASA's Destination Station Exhibit Shares The Wonders Of The International Space Station
PR Newswire - Tue Jan 07, 1:41PM CST
OPENS JANUARY 24, 2014 AT THE CALIFORNIA SCIENCE CENTER
Nasdaq stocks posting largest percentage decreases
AP - Mon Jan 06, 12:39PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Accreditations, Stock Price Movements, Reimbursement Coverage, and Conference Presentation Schedules - Research Report on Cigna, CareFusion, Health Management, MiMedx Group, and Merrimack
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Cigna Corp. (NYSE: CI), CareFusion Corporation (NYSE: CFN), Health Management Associates Inc. (NYSE: HMA), MiMedx Group, Inc. (NASDAQ: MDXG), and Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx
PR Newswire - Thu Apr 10, 11:30AM CDT
On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11% to 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 673.27, up 2.11%, and the same has advanced 2.86% in the last three months. Investor-Edge has initiated coverage on the following equities: Seattle Genetics Inc. (NASDAQ: SGEN), Theravance Inc. (NASDAQ: THRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX) and MiMedx Group Inc. (NASDAQ: MDXG). Free technical research on SGEN, THRX, NBIX and MDXG can be downloaded upon signing up at:
MiMedx First Quarter Revenue Exceeded Upper End Of Guidance
PR Newswire - Mon Apr 07, 7:30AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its first quarter of 2014 revenue slightly exceeded the upper end of its previously announced guidance. The Company also announced its guidance for the second quarter of 2014.
MiMedx Group, Inc. Announces Release Date for 2014 First Quarter Results
PR Newswire - Wed Apr 02, 1:23PM CDT
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the first quarter ended March 31, 2014, will be released before the opening of the market on Friday, April 25, 2014. MiMedx will host a live broadcast of its first quarter conference call on Friday, April 25, 2014 at 10:30am EDT. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website at www.mimedx.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com.
MiMedx to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Fri Mar 28, 1:22PM CDT
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 13th Annual Needham Healthcare Conference in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, April 8th at 3:00 p.m. EDT, at the Westin NY Grand Central Hotel. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx Schedules Shareholder Call To Update Progress Of FDA Discussions, Reimbursement Successes And Recent Short-Selling Initiatives
PR Newswire - Mon Mar 24, 7:34AM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it will host a shareholder call tomorrow, Tuesday, March 25, 2014 at 11:00 AM Eastern Time to update shareholders on the positive progress of its discussions with the Food and Drug Administration ("FDA"
regarding the Company's micronized allograft. During the call, the Company also plans to provide updates on its progress with wound care reimbursement, its sales force expansion, as well as its reaction to the misinformation in certain recent short-selling related blogs. MiMedx to Present at 2nd Annual Regen Med Investor Day
PR Newswire - Mon Mar 17, 10:31AM CDT
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 2nd Annual Regen Med Investor Day in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Wednesday, March 26th, 3:45 p.m. EDT, at the Metropolitan Club. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx EpiFix® Allograft Receives Medicare Coverage From The Final Medicare Contractor
PR Newswire - Thu Mar 13, 1:11PM CDT
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, First Coast Service Options, Inc. ("FCSO"
, has confirmed that the Company's wound care allograft, EpiFix®, has been approved for coverage when applied in the hospital outpatient and ambulatory surgery center settings. MiMedx To Present At 2014 Canaccord Genuity Musculoskeletal Conference
PR Newswire - Tue Mar 04, 3:52PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 2014 Canaccord|Genuity Musculoskeletal Conference in New Orleans, Louisiana. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Tuesday, March 11th at 10:00am CDT/11:00am EDT, at the Sheraton New Orleans. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MiMedx Announces Record 2013 Results
PR Newswire - Wed Feb 26, 6:30AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the year ended December 31, 2013.
MiMedx Sponsored Osteoarthritis Study Using PURION® Processed Amniotic Tissue Published In Arthritis Research & Therapy
PR Newswire - Tue Feb 25, 7:10PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today a MiMedx-sponsored study from Georgia Institute of Technology has been published in Arthritis Research & Therapy. The article, titled "Intra-articular injection of micronized dehydrated human amnion/chorion membrane attenuates osteoarthritis development" was authored by Nick Willett, Tanushree Thote, Angela Lin, Shamus Moran, Yazdan Raji, Sanjay Sridaran, Hazel Stevens and Robert Guldberg. The electronic publication of the study is available at http://arthritis-research.com/content/16/1/R47.
Second MiMedx EpiFix® Randomized Comparative Study Published In International Wound Journal Shows 92.5% Healing Rate Over 12 Weeks
PR Newswire - Tue Feb 25, 6:07PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "A prospective, randomized comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers" has been published electronically in the International Wound Journal. The study manuscript was authored by Charles M. Zelen, DPM, FACFAS; Thomas E. Serena MD, FACS; and Robert J. Snyder, DPM, MSc.
MiMedx EpiFix® Allograft Awarded Coverage by HCSC
PR Newswire - Wed Feb 12, 7:30AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Health Care Services Corporation (HCSC) has confirmed that the Company's EpiFix® allograft has been awarded reimbursement coverage. HCSC is the largest customer-owned health insurance company in the United States with nearly 14 million members.
RXi Pharmaceuticals Announces Listing on NASDAQ Capital Market
PR Newswire - Tue Feb 11, 6:02AM CST
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced today that the Company received approval by The NASDAQ Stock Market LLC's ("NASDAQ"
Listing Qualification Department to list its common stock on the NASDAQ Capital Market. The Company's common stock will commence trading under the same ticker symbol, "RXII," on the NASDAQ Capital Market effective at the opening of trading on Tuesday, February 11, 2014. MiMedx EpiFix® Allograft Receives Reimbursement Coverage From The 7th Of The 8 Medicare Contractors
PR Newswire - Mon Feb 10, 8:03AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Medicare contractor, Noridian Healthcare Solutions, LLC, has confirmed that the Company's wound care allograft, EpiFix®, has been approved to receive reimbursement coverage.
MiMedx Addresses Misrepresentations In Seeking Alpha Article
PR Newswire - Fri Feb 07, 2:43PM CST
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, today issued the following statement regarding a blog post published today on Seeking Alpha.
MiMedx Announces Release Date For 2013 Full Year Results
PR Newswire - Tue Jan 21, 10:08AM CST
MiMedx (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the fourth quarter and year ended December 31, 2013, will be released before the opening of the market on Wednesday, February 26, 2014. MiMedx will host a live broadcast of its fourth quarter and year-end conference call on Wednesday, February 26, 2014 at 10:30am EST. A listen-only simulcast of the MiMedx conference call will be available online at the Company's website at www.mimedx.com or at www.earnings.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at www.mimedx.com or www.earnings.com.
MiMedx to Present at 32nd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Jan 13, 10:23AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced the schedule for its presentation at the 32nd Annual J.P. Morgan Healthcare Conference. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, will present on Thursday, January 16, 2014, 9:00am PST, at the Westin St. Francis Hotel in San Francisco. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
NASA's Destination Station Exhibit Shares The Wonders Of The International Space Station
PR Newswire - Tue Jan 07, 1:41PM CST
OPENS JANUARY 24, 2014 AT THE CALIFORNIA SCIENCE CENTER
Nasdaq stocks posting largest percentage decreases
AP - Mon Jan 06, 12:39PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Accreditations, Stock Price Movements, Reimbursement Coverage, and Conference Presentation Schedules - Research Report on Cigna, CareFusion, Health Management, MiMedx Group, and Merrimack
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Cigna Corp. (NYSE: CI), CareFusion Corporation (NYSE: CFN), Health Management Associates Inc. (NYSE: HMA), MiMedx Group, Inc. (NASDAQ: MDXG), and Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
